ASF Research Grants
ASF Research Grants support scientists and clinicians studying Angelman syndrome, funding research on UBE3A, therapies, care, and biomarkers to advance treatments and improve quality of life.
Browse similar grants
Funder: Angelman Syndrome Foundation
Due Dates: September 1, 2026 (2026 review cycle) | August 15, 2027 (Annual deadline)
Funding Amounts: Up to $100,000 per year for one- or two-year grants, including indirect costs
Summary: Supports Angelman syndrome research on UBE3A, therapeutic development, clinical care, and biomarkers to advance treatments and improve quality of life.
Key Information: Grants are awarded to institutions, and funded projects must be ready to begin no later than March 31.
Description
The Angelman Syndrome Foundation (ASF) funds scientific studies that advance understanding of Angelman syndrome (AS), accelerate effective treatments, and improve care across the lifespan. Its annual call invites scientists and clinicians worldwide to propose innovative research aligned with the 2025 ASF Research Roadmap.
The roadmap prioritizes four pillars: UBE3A regulation and function, cutting-edge therapeutic strategies, clinical care and innovation, and therapeutic endpoints and biomarkers. Supported directions include molecular and genetic studies, UBE3A activation and gene delivery, preclinical therapeutic development, pharmacological and combination therapies, and interventions addressing sleep, seizures, and motor challenges. ASF also prioritizes accessible care models, validated measures of motor, communication, cognitive, and behavioral function, and biomarkers of disease progression and treatment response. Collaboration and use of LADDER data support translation into meaningful improvements in daily life.
